AstraZeneca's CEO says the company needs to conduct another global trial for its vaccine. That's according to a report from Bloomberg.
AstraZeneca initially said its vaccine showed 62 percent effectiveness when taken as a full two-dose regimen.
It also said the vaccine was up to 90 percent effective when participants were given a dose and a half. But the difference in dosages was apparently a mistake.
Some of the vials used in the trial had a lower concentration of the vaccine.
AstraZeneca's CEO wants to administer that one-and-a-half dosage intentionally and see if the 90 percent efficacy results hold up.
